Clinical Trial Update: Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics and pharmacodynamics of lapatinib given in two dosing regimens in treatment-naive breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 1 | Status: COMPLETED